Temporal Concept
FDA clears its first prescription migraine app, from Click Therapeutics
United States Food and Drug Administration, CT-132, Migraine Disorders, Click Therapeutics, click, first
Sanofi pens $1.8B research deal for 2 bispecific antibodies aimed at autoimmune, immunology
Antibodies, Bispecific, Autoimmune, Inflammatory Bowel Diseases, sanofi, Earendil Labs, Immunology, Collaboration, development aspects
RFK Jr. attacks environmental toxins as cause of childhood autism ‘epidemic’, stays silent on vaccines
Autistic Disorder, Vaccines, Kennedy, Environment, RFK gene, HHS
Former FDA Officials Sound Alarm: Visible Changes May Be Tip of the Iceberg
United States Food and Drug Administration, public health medicine (field), Changing, Vaccines, Leadership, Policy, drug safety, Previous, KAT5 wt Allele, Icebergs, Disease Outbreaks, Alarm device, Visible
Pharma’s wins and losses in Trump’s sprawling executive order on drug prices
Medicare, Medicare, Industry, drug price, Mediation, small molecule drugs, losses, IRA, Insulin, Prices
CDC advisors broaden RSV vaccine recommendations to at-risk adults in their 50s
Adult, Respiratory syncytial virus, Centers for Disease Control and Prevention (U.S.), Vaccines, Recommendation, Age, Arexvy, Chronic Condition, Severe (severity modifier), 50–59, broaden
Glycomine raises $115M to see if it can treat rare glycosylation disorder
Infrequent, GLM101, Glycomine, Congenital disorder of glycosylation type 1A
Ayrmid misses deadline for detailed offer to top private equity bid for bluebird
Ayrmid, Family Turdidae (organism), gene therapy, Failed, Capital, proposal – intent, United States Food and Drug Administration, private equity, deadline
Trump pledges his support for a change to the IRA long sought by drugmakers
IRA, Medicare, Contraceptives, Oral, Mediation, Industry, drug price, Biological Factors, Prices, drugmakers, Medicare
Navigating the Biotech Winter: Strategies for Survival and Growth Amid Ongoing Industry Downturn
biotech downturn, layoff trends, funding challenges, strategic adaptation, innovation, mergers & acquisitions, workforce planning, precision medicine, artificial intelligence, regulatory landscape, survival strategies, growth opportunities